Datasets:

ESGBERT

/

base_data

like 2

Follow

ESGBERT 25

From these efforts, we developed the Alexion CSR-STAR Platform as our structural framework, along with a series of corresponding aspirations and performance metrics.

In 2019, Alexion formalized aspirations and accompanying metrics aligned with our CSR-STAR Platform.

Even though these formal aspirations and metrics were recently established, our teams have been committed to many of these areas of focus since the company’s founding.

For most areas, as the baseline year against which we will measure progress, with the exception of two environmental metrics for which the baseline year will be 2020.

Moving forward, we plan to report yearly progress against these aspirations in our annual CSR report.

Recognizing the importance of corporate social responsibility at Alexion, we are pleased to publish Alexion’s first CSR report.

We expect to update this report on an annual basis.

This report references the Global Reporting Initiative (GRI) Standards from the Sustainability Accounting Standards Board (SASB).

This report focuses primarily on activities from calendar year indicated otherwise, performance metrics are as of Dec. 31, 2019.

Quantitative metrics cover all entities contained in our consolidated financial statements.

Qualitative narrative may be global, regional or within a given country, depending on the topic area.

Questions or comments regarding this report should be directed to [email protected].

in CSR reporting, as described in the GRI Standards, is lower than the threshold for information that must be disclosed in mandatory f inancial disclosures, such as the Form 10-K.

The topics considered in the CSR materiality assessment were developed based on matters identified by a cross section of internal and external stakeholders, as well as a review of key frameworks such as GRI and SASB and the material topics published by peer companies and CSR leaders.

More than 60 internal and 30 external stakeholders were queried in this process.

Patient organizations, investors, former regulators, community groups, environmental NGOs, recruitment f irms and research organizations were engaged to prioritize the topics.

The results of this assessment informed both our CSR-STAR Platform and the content of this report.

AT ALEXION, among the ways we’re working toward a brighter future is by supporting strong communities and a healthy environment.

well-being of our company and our many stakeholders.

the local communities around the world where our employees live and work through strategic charitable giving, engaging with nonprofits and educational institutions, and through employee volunteerism.

GIVING BACK IN MULTIPLE WAYS Alexion has long been invested in our communities.

approach to be more strategically focused so that our charitable giving may have the maximum positive impact.

We do this through two main impact areas: the Alexion Charitable Foundation and Corporate Giving.

These avenues are separate from, and in addition to, our patient support programs (see Page engagement with various patient organizations.

The mission of the recently formed Alexion Charitable Foundation is to offer promise and cultivate a sense of belonging – particularly for people affected by a rare disease – through initiatives that advance emotional well-being, educational opportunities and economic relief.

For purposes of the Foundation’s charitable giving, it defines “rare disease” by disease states listed in the Global Genes’ RARE List.

Within this context, there are two areas through which we provide funding.

education and job skills support, and help alleviate some key economic burdens.

These third parties will award and distribute monetary grants to individuals and organizations in alignment with the Rare BelongingTM suite of funding priorities.

Alexion community partner URU, The Right to Be, Inc. debuts their "You Can't Be What You Can't See" virtual reality learning experience at URU's Changing the Face of STEM initiative in Dallas, Texas.

Mental health counseling: Connecting the rare disease community with mental health professionals, supporting mental health tracks at conferences and providing conference tuition assistance.

• Education and job skills: Supporting educational needs for school-age children and young adults, and career reskilling for newly diagnosed adults in the rare community.

Providing transportation and accommodations funding for pressing, nonmedical and medically related needs.

of critical need, such as natural disasters or significant, unplanned expenses.

to organizations in the communities where Alexion has a major presence, but without the strict requirement of benefiting the rare disease community.

Local Needs funding focuses on helping people who are disadvantaged or disenfranchised.

This enables the Foundation to positively impact the communities where we live and work.

Advancing emotional well-being through mental health and other social services.

• Advancing educational opportunities through basic education, science, technology, engineering and math (STEM) education, job readiness and other skills.

• Advancing the cause of diversity and inclusion in society and critical institutions.

The guidelines for Alexion’s Corporate Giving program are similar in focus to the Local Needs Grants of the Alexion Charitable Foundation.

Alexion’s Corporate Giving mission is to positively impact our local communities — with a particular focus on people who are disadvantaged or disenfranchised — through initiatives that advance emotional well-being, provide educational opportunities and promote diversity and inclusion in society and critical institutions.

As a company, Alexion’s positive impact reaches beyond just the dollars we contribute.

to benefit people affected by a rare disease – including patients, their families and caregivers.

To align our employee volunteer efforts with our broader philanthropic strategy, we developed a formal Global Volunteer Policy in 2019.

Global Day of Service is Alexion’s annual companywide volunteer campaign.

in mentoring students, preparing meals, planting gardens, packing hygiene kits and working on a variety of beneficial activities with children, teens, adults and senior citizens.

In addition to our companywide Global Day of Service, individual Alexion offices organize their own local initiatives aligned with our Corporate Giving mission.

In to Science from Scientists, whose mission is to teach and inspire the next generation of students by improving STEM literacy.

We also became a founding member of Life Science Cares, a collective industry effort to help address the impact of poverty and inequality in Greater Boston.

a book drive for More Than Words, a nonprofit that empowers at-risk youth, and a grocery drive to help local families during the holiday season.

Big Sister Association of Greater Boston's Workplace Mentoring Program.

The program matches volunteer employees from partner companies with middle-school students in Boston Public Schools.

with their Little Sister during the academic school year.

Bogart, Georgia, U.S. ► Employees at Alexion’s manufacturing facility in Bogart partnered with a local food bank, working alongside the Food Bank of Northeast Georgia’s coordinators on a monthly basis to sort canned goods, package donated produce and prepare meals for families, schools, children and shelters.

and their families living with a serious illness.

From my perspective, working for a company that supports society beyond its customers means working for a company that shares my values.

For the past two years, Alexion employees in Zurich have worked with PluSport, Switzerland’s umbrella organization for handicapped sports and recreation among all ages and abilities.

a brighter future for both present and future generations.

We’re committed to excellence in managing and reducing our environmental footprint.

our commitment to environmental stewardship and the health and safety of our colleagues and communities.

All employees and contractors are covered by this Policy.

Guided by our EHS Policy, Alexion manages EHS in alignment with widely accepted global standards like ISO 14001.

Our global EHS management system guides our actions and tracks key performance indicators to manage our risks and drive continuous improvement.

This section of the report focuses on the environmental aspects of our operations.

Alexion has achieved zero process wasteto-landfill status enterprise-wide, and we aim to maintain this status year over year.

We aim to minimize process waste wherever feasible and practical by eliminating or reducing, reusing and recycling material where possible, and recovering, treating and disposing of material if other options are not technically feasible.

Plastic recycled from our New Haven facility is turned into park benches, pallets, speed bumps and other beneficial uses.

Alexion has two Leadership in Energy and Environmental DesignTM (LEED®) buildings, located in New Haven, Connecticut, and Boston, Massachusetts.

LEED provides a framework for creating healthy, highly efficient and cost-saving green buildings.

Alexion’s manufacturing facility in Athlone, Ireland, implemented a reverse osmosis water recovery process to purify and reuse water that may otherwise not be clean enough for Alexion’s production standards.

energy usage for process cooling systems, Alexion was able to improve the energy efficiency of its manufacturing operations.

Our ambition is to move a portion of our manufacturing in-house.

We are currently seeking regulatory approval for two recently completed biologics facilities in Ireland.

This shift, commenced in will change our direct environmental footprint.

All greenhouse gas emissions are measured in metric tons of carbon dioxide equivalent (metric tons CO₂e) and follow the Intergovernmental Panel on Climate Change (IPCC), Fourth Assessment.

+ Fuel Oil Generators (mmBtu Fuel Oil x Emissions Factor [for kilograms to metric tons).

For Scope the following formula: Electricity (MWh) x Emissions Factor (558.2 lb.

For Scope following formula: Electricity (MWh) x Emissions Factor (1089.4 lb.

pursuit of brighter futures for all of our stakeholders.

Every day we urgently seek to understand patient journeys, find answers and collaborate to deliver access to therapies that can change the lives of people living with rare diseases.

Alexion’s vision is to continuously raise the bar to deliver on patient expectations with solutions designed for them as people – meaning we want to take the time to understand their social and emotional lives, as well as their medical condition.

and method to accelerate the development of enterprise-wide solutions and integrate internal and external insights on the patient experience.

together internal and external stakeholders to identify and solve urgent patient challenges.

an enterprise-wide model for deepening our understanding of the patient and stakeholder journeys.

accounts of their experiences, emotions and ethnography insights.

It’s a totally different approach where rather than promoting our messages for their response, we humbly listen to continuously understand challenges patients and stakeholders face and the best way we can serve them.

data collection, analysis and publication, and acknowledge patient authorship.

for scientific journals, which we expect will become a standard practice.

As part of our ULTOMIRIS® (ravulizumab- cwvz) subcutaneous program, we collected patient feedback on the device used in the program to understand human factors, appeal and convenience.

in a clinical trial in adults with HPP.

After participating in a clinical trial for SOLIRIS® (eculizumab), her voice, ability to chew and swallow, and fatigue improved, and she was able to return to work after nearly struggling with her symptoms.

and provides an opportunity for idea sharing and internal knowledge building, while protecting individual privacy.

The impact of rare diseases on patients and their families is profound.

with a rare condition can compound the difficulty.

in Alexion patient support programs year over year, regardless of whether they are using our therapies.

Meet Tanner When Tanner was born, his mother, René, did not suspect anything was wrong with him.

he participated in a clinical trial for STRENSIQ® (asfotase alfa).

Years later, Tanner is doing well and continues to receive treatment with STRENSIQ.

about their disease by providing patient support programs that help people living with a rare disease to better manage their symptoms, understand their treatment and improve their overall health.